Publication: The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
Submitted Date
Received Date
Accepted Date
Issued Date
2020-01-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
11791322
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85084211127
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Cancer Management and Research. Vol.12, (2020), 2491-2499
Citation
Napat Saigosoom, Doonyapat Sa-Nguanraksa, Eng O-Charoenrat, Thanawat Thumrongtaradol, Pornchai O-Charoenrat (2020). The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy. Retrieved from: https://hdl.handle.net/20.500.14594/56307.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
© 2020 Saigosoom et al. Background and Purpose: Magee Equations have been developed as accurate tools for predicting response and clinical outcomes in breast cancer patients treated with adjuvant systemic therapy using basic clinicopathological parameters. This study aims to evaluate the alternative application of Magee Equation 2 score in predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive, HER2- negative breast cancer. Patients and Methods: Patients with HR-positive, HER2-negative breast cancer who received NAC from January 2010 to May 2018 at Siriraj Hospital, Mahidol University, Thailand, were recruited. Pre-treatment status of HR andHER2was used to calculate the Magee Equation 2 scores. The pCR rates among different clinicopathological parameters were analyzed. Survival analysis was performed by Log-rank test. Kaplan-Meier survival curves were analyzed. Results: A total of 215 patients were eligible. The pCR rates for low, intermediate, and high scores were 4.8%, 3.6%, and 23.8%, respectively. Patients with high scores had significantly higher size reduction and pCR rates compared to those with intermediate or low scores (p<0.001). Those with high scores had higher rates of locoregional recurrence and death. The patients with high score had significantly lower overall survival (p=0.034). Conclusion: Among patients with HR-positive and HER2-negative breast cancer treated with NAC, Magee Equation 2 might be used as a tool for predicting the pCR and clinical outcome.